mark gordon glutathione R. Gordon, DDS, MS EOne Acquires 51% Stake in
EOne Acquires 51% Stake in the Mark Gordon Co. for $133 Million Mark Gordon NCDMM DR. MARK GORDON DISCUSSES NEUROENDOCRINOLOGY Frontiers Glutathione and neurodegenerative diseases: immunopharmacological implications Mark Gordon Drug Development Executive Neurologist Clinical & Translational CNS Strategy & Development Leader Neurodegenerative & Movement Disorders Expert LinkedIn
Pay in 4 interest-free payments of $5.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19



